SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Mimedx Group, Inc. – ‘10-K’ for 12/31/12 – ‘R45’

On:  Friday, 3/15/13, at 5:14pm ET   ·   For:  12/31/12   ·   Accession #:  1140361-13-12765   ·   File #:  0-52491

Previous ‘10-K’:  ‘10-K/A’ on 6/21/12 for 12/31/11   ·   Next:  ‘10-K’ on 3/4/14 for 12/31/13   ·   Latest:  ‘10-K’ on 2/28/24 for 12/31/23

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/15/13  Mimedx Group, Inc.                10-K       12/31/12   70:10M                                    Broadridge Fin’l So… Inc

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Mimedx Group Inc 10-K 12-31-2012                    HTML   1.04M 
 2: EX-10.54    Material Contract                                   HTML     39K 
 3: EX-10.55    Material Contract                                   HTML     27K 
 4: EX-10.56    Material Contract                                   HTML     96K 
 5: EX-23.1     Consent of Experts or Counsel                       HTML     19K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     27K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     27K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     21K 
 9: EX-32.2     Certification -- §906 - SOA'02                      HTML     21K 
47: R1          Document and Entity Information                     HTML     48K 
37: R2          Consolidated Balance Sheets                         HTML    126K 
45: R3          Consolidated Balance Sheets (Parenthetical)         HTML     56K 
49: R4          Consolidated Statements of Operations               HTML     70K 
64: R5          Consolidated Statements of Stockholders' Equity     HTML    130K 
39: R6          Consolidated Statements of Stockholders' Equity     HTML     22K 
                (Parenthetical)                                                  
44: R7          Consolidated Statements of Cash Flows               HTML    150K 
34: R8          Consolidated Statements of Cash Flows               HTML     76K 
                (Parenthetical)                                                  
26: R9          Nature of Business                                  HTML     24K 
66: R10         Significant Accounting Policies                     HTML    124K 
51: R11         Liquidity and Management's Plans                    HTML     22K 
50: R12         Acquisition of Surgical Biologics, LLC              HTML     85K 
55: R13         Inventories                                         HTML     33K 
56: R14         Property and Equipment                              HTML     36K 
54: R15         Intangible Assets and Royalty Agreement             HTML     96K 
57: R16         Accrued Expenses                                    HTML     30K 
46: R17         Long-Term Debt                                      HTML     54K 
48: R18         Common Stock Placements                             HTML     36K 
53: R19         Equity                                              HTML    185K 
70: R20         Income Taxes                                        HTML     58K 
60: R21         Related Party Transactions                          HTML     38K 
41: R22         401k Plan                                           HTML     30K 
52: R23         Commitments                                         HTML     30K 
43: R24         Subsequent Events                                   HTML     24K 
20: R25         Significant Accounting Policies (Policies)          HTML    222K 
61: R26         Significant Accounting Policies (Tables)            HTML     65K 
67: R27         Acquisition of Surgical Biologics, LLC (Tables)     HTML     72K 
30: R28         Inventories (Tables)                                HTML     30K 
29: R29         Property and Equipment (Tables)                     HTML     33K 
32: R30         Intangible Assets and Royalty Agreement (Tables)    HTML     96K 
33: R31         Accrued Expenses (Tables)                           HTML     27K 
35: R32         Long-Term Debt (Tables)                             HTML     47K 
19: R33         Equity (Tables)                                     HTML    182K 
58: R34         Income Taxes (Tables)                               HTML     50K 
40: R35         Related Party Transactions (Tables)                 HTML     33K 
42: R36         Commitments (Tables)                                HTML     25K 
23: R37         Nature of Business (Details)                        HTML     21K 
69: R38         Significant Accounting Policies (Details)           HTML    157K 
16: R39         Liquidity and Management's Plans (Details)          HTML     31K 
36: R40         Acquisition of Surgical Biologics, LLC (Details)    HTML    177K 
63: R41         Inventories (Details)                               HTML     38K 
22: R42         Property and Equipment (Details)                    HTML     34K 
28: R43         Intangible Assets and Royalty Agreement (Details)   HTML    122K 
31: R44         Accrued Expenses (Details)                          HTML     31K 
38: R45         Long-Term Debt (Details)                            HTML    116K 
18: R46         Common Stock Placements (Details)                   HTML     70K 
25: R47         Equity (Details)                                    HTML    285K 
17: R48         Income Taxes (Details)                              HTML     95K 
62: R49         Related Party Transactions (Details)                HTML     31K 
21: R50         401k Plan (Details)                                 HTML     32K 
59: R51         Commitments (Details)                               HTML     28K 
24: R52         Subsequent Events (Details)                         HTML     37K 
68: XML         IDEA XML File -- Filing Summary                      XML     94K 
27: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS   1.52M 
10: EX-101.INS  XBRL Instance -- mdxg-20121231                       XML   2.21M 
12: EX-101.CAL  XBRL Calculations -- mdxg-20121231_cal               XML    193K 
13: EX-101.DEF  XBRL Definitions -- mdxg-20121231_def                XML    640K 
14: EX-101.LAB  XBRL Labels -- mdxg-20121231_lab                     XML   2.22M 
15: EX-101.PRE  XBRL Presentations -- mdxg-20121231_pre              XML   1.17M 
11: EX-101.SCH  XBRL Schema -- mdxg-20121231                         XSD    203K 
65: ZIP         XBRL Zipped Folder -- 0001140361-13-012765-xbrl      Zip    225K

‘R45’   —   Long-Term Debt (Details)

This is an IDEA Financial Report.  [ Alternative Formats ]

 
v2.4.0.6
Long-Term Debt (Details) (USD $)
 1 Months Ended 12 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 2 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 0 Months Ended 1 Months Ended 12 Months Ended 2 Months Ended 12 Months Ended
Convertible Line of Credit with Related Party [Member]
Convertible Line of Credit with Related Party [Member]
First Contingent Warrants [Member]
Convertible Line of Credit with Related Party [Member]
First Contingent Warrants [Member]
Convertible Line of Credit with Related Party [Member]
Second Contingent Warrants [Member]
Convertible Line of Credit with Related Party [Member]
Chairman and CEO [Member]
Convertible Line of Credit with Related Party [Member]
4% Convertible Debt [Member]
4% Convertible Debt [Member]
5% Convertible Senior Secured Promissory Note [Member]
5% Convertible Senior Secured Promissory Note [Member]
5% Convertible Senior Secured Promissory Note [Member]
5% Convertible Senior Secured Promissory Note [Member]
First Contingent Warrants [Member]
5% Convertible Senior Secured Promissory Note [Member]
First Contingent Warrants [Member]
5% Convertible Senior Secured Promissory Note [Member]
Second Contingent Warrants [Member]
5% Convertible Senior Secured Promissory Note [Member]
Second Contingent Warrants [Member]
5% Convertible Senior Secured Promissory Note [Member]
Second Contingent Warrants [Member]
5% Convertible Senior Secured Promissory Note [Member]
Chairman and CEO [Member]
5% Convertible Senior Secured Promissory Note [Member]
Chairman and CEO [Member]
Debt Instrument [Line Items]                                            
Total debt   $ 5,313,645 $ 7,649,773   $ 0 [1] $ 1,342,726 [1]         $ 0 $ 1,299,315   $ 5,313,645 [2] $ 5,007,732 [2]              
Less unamortized debt discount   (1,301,203) (2,480,400)                                      
Less current portion   0 (2,424,786)                                      
Long-term portion   4,012,442 2,744,587                                      
Annual interest rate (in hundredths)       4.00%   5.00%           4.00%   5.00% 5.00%              
Maturity date           Dec. 31, 2012           Jul. 05, 2012   Dec. 31, 2013                
Additional interest payment (in hundredths)                           5.00%                
Shares issued in conjunction with conversion of convertible debt (in shares)         893,267         1,403,630                        
Repayments of Convertible Promissory Notes 177,000 427,126 0               177,000                      
Percentage of equity securities to be sold for conversion of notes (in hundredths)                                 25.00%     25.00%    
Warrant exercise price (in dollars per share)           $ 1.00               $ 1.09     $ 0.01     $ 0.01    
Warrants vested (in shares)             325,000                 1,250,000            
Warrants voided (in shares)                 325,000                   1,250,000      
Closing trading price of Company stock (in dollars per share)                                   $ 1.75        
Number of consecutive trading days                                     10 days      
Beneficial Conversion Feature Value Related To Convertible Debt Issued With Regard To Senior Secured Promissory Notes     2,278,052         594,456                 2,278,052          
Additional financing expense   437,500                                        
Warrant exercise price (in dollars per share)           $ 1.00               $ 1.09     $ 0.01     $ 0.01    
Proceeds from issuance of debt                             5,000,000             500,000
Convertible debt, shares issuable if converted (in shares)                             5,000,000              
Placement fee                           32,800                
Placement fee, warrants issued (in shares)   1,120,000                       42,400                
Warrants term   5 years                       5 years                
Fair value of placement fee warrants                           15,000                
Direct costs of sale of notes                           $ 47,800                
Convertible secured promissory note to common stock (in shares)   893,267                     5,271,963               532,260  
[1] The same terms offerred to the Senior Secured Promissory note with regard to Contingent Warrants applied to the Convertible Line of Credit. In March 2012 a total of 325,000 First Contingent Warrants vested. In July 2012, a total of 325,000 Second Contingent Warrants were voided. The amount of the warrants (i.e. the exercisable First Contingent Warrants) and beneficial conversion feature totaled $594,456 which has been recorded as a debt discount that has been charged to interest expense using the effective interest rate over the life of the note.
[2] Investors received First Contingent Warrants (25% of amount invested) and Second Contingent Warrants (25% of amount invested) at an exercise price of $.01 per share. The warrants vest depending upon reported Company revenues for the Years ended December 31, 2011 and 2012. In March 2012 a total of 1,250,000 First Contingent Warrants were vested. In July 2012, a total of 1,250,000 Second Contingent Warrants were voided due to the Company share price trading at or above $1.75 for ten consecutive trading days. The amount of the warrants (i.e. the exercisable First Contingent Warrants) and beneficial conversion feature totaled $2,278,052 which has been recorded as a debt discount that has been and will continue to be charged to interest expense using the effective interest rate over the life of the note.

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
12/31/1310-K,  10-K/A
Filed on:3/15/13
2/28/13
For Period end:12/31/12
7/31/12
7/5/12
7/3/124
3/31/1210-Q
12/31/1110-K,  10-K/A
1/5/114,  8-K,  8-K/A
9/15/094
 List all Filings 
↑Top
Filing Submission 0001140361-13-012765   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Sat., Apr. 27, 10:52:50.1am ET